Ojjaara (momelotinib): GSK’s myelofibrosis drug gains new momentum with VEXAS focus

Responsible: ad hoc news Lifestyle & Consumer Desk. Reviewed prior to publication on June 12, 2026 at 7:52:33 PM ET. Details in the imprint.

Ojjaara, the brand name for GSK’s momelotinib, is back in the spotlight after the JAK-inhibitor received Orphan Drug Designation from both the US Food and Drug Administration and the European Medicines Agency for the treatment of VEXAS syndrome, a rare and life-threatening haemato-inflammatory disease with no approved therapies today. For US patients and families facing myelofibrosis and now VEXAS, the drug is emerging as one of the more closely watched targeted treatments in GSK’s hematology portfolio. Momelotinib is already approved in the US under the name Ojjaara for adults with intermediate- or high-risk myelofibrosis and anemia, and is available by prescription through hematologists and specialty pharmacies. With the VEXAS designation, GSK is signaling that it wants to expand the reach of this therapy from established myelofibrosis use into a second rare-disease setting where clinical need remains acute.

How Ojjaara is used today in myelofibrosis care

Ojjaara (momelotinib) is a once-daily oral JAK inhibitor with a differentiated mechanism of action targeting JAK1, JAK2 and ACVR1, designed specifically for adults living with myelofibrosis who also have anemia. In the US, the drug is approved for the treatment of intermediate- or high-risk myelofibrosis with anemia in adults, a patient group that often struggles not only with spleen enlargement and systemic symptoms, but also with transfusion-dependent anemia and significant fatigue. According to GSK, myelofibrosis itself is a rare form of blood cancer in which scar tissue forms in the bone marrow, disrupting normal blood cell production and leading to low red blood cell counts, weakness, night sweats and an enlarged spleen. Ojjaara’s label is intended to address this intersection of disease burden and anemia, offering a targeted option particularly for patients who may not tolerate or benefit from older therapies focused only on spleen size reduction.

The clinical rationale for momelotinib hinges on its ability to inhibit signaling through JAK pathways that drive inflammatory cytokine production, as well as ACVR1, a receptor linked to hepcidin regulation and iron metabolism. By modulating these pathways, the drug aims to control hallmark symptoms of myelofibrosis such as spleen enlargement and constitutional complaints, while also helping improve anemia and reduce transfusion needs. Data cited by GSK from late-stage studies, which underpinned approvals in the US, EU, UK and Japan, showed that momelotinib delivered clinically meaningful spleen volume reductions and symptom improvements in a significant portion of patients, alongside benefits on anemia endpoints. While specific response numbers for US-label populations vary by trial and are not always easily comparable across competing JAK inhibitors, the company positions Ojjaara as a differentiated option particularly where anemia is part of the clinical picture.

From the patient’s perspective, the day-to-day experience of Ojjaara is shaped by its once-daily oral dosing and the need for ongoing monitoring of blood counts, liver function and potential side effects, including infections, cytopenias and gastrointestinal complaints, which are consistent with the JAK-inhibitor class. Prescribers typically integrate the drug into a broader care plan that may involve transfusions, iron management, symptom-directed medicines and regular imaging or physical exams to track spleen size. For US payers and specialty pharmacies, Ojjaara slots into the existing category of oncology and hematology oral targeted therapies, where prior authorization and evidence of intermediate- or high-risk disease with anemia are commonly required before dispensing. The exact list price for Ojjaara in the US is not detailed in the latest GSK release, but it falls into the high-cost specialty drug bracket typical for oral hematology treatments, with final out-of-pocket costs for patients dependent on insurance coverage, co-pay programs and assistance from GSK support initiatives.

Globally, momelotinib has secured approvals beyond the US market, a point GSK highlights to underscore its role as an established therapy rather than an early-stage pipeline bet. In the European Union and the UK, the medicine is approved for the treatment of myelofibrosis with disease-related splenomegaly or symptoms in adults who have moderate to severe anemia, aligning broadly with the US positioning but reflecting regional regulatory language. In Japan, regulatory authorities have cleared momelotinib for the treatment of myelofibrosis, extending its footprint into another major market for hematology drugs. These approvals mean that, while indications and exact wording differ by region, the core use case is consistent: targeting myelofibrosis patients whose anemia complicates both day-to-day living and treatment choices. For US patients who move or seek treatment abroad, this international regulatory footprint can be relevant when physicians evaluate continuity of care and access, even though reimbursement and clinical guidelines are country-specific.

For US consumers and caregivers attempting to understand how Ojjaara fits into the broader treatment landscape, it sits alongside other JAK inhibitors and supportive therapies that are used to manage myelofibrosis symptoms and complications. While individual clinical decisions are made by physicians, GSK’s messaging emphasizes that momelotinib addresses both spleen and symptom control and anemia in one oral agent, a combination that can be attractive in everyday practice where reducing transfusion burden is a key goal. Current US professional guidelines and payer policies typically emphasize evidence from randomized trials and post-marketing safety data, areas where GSK continues to invest through ongoing studies and real-world evidence programs. Patients and doctors often weigh these data against the side-effect profile, long-term safety considerations of JAK inhibition and personal factors like age, comorbidities and goals of care when deciding whether to start or continue Ojjaara.

Orphan Drug Designation in VEXAS: new potential use for momelotinib

The most recent milestone for momelotinib is its Orphan Drug Designation in both the US and the EU for VEXAS syndrome, formally known as Vacuoles, E1 enzyme, X-linked, Autoinflammatory, Somatic syndrome. VEXAS is a rare haemato-inflammatory disease characterized by systemic inflammation, bone marrow vacuoles and blood cell abnormalities, caused by somatic mutations in the UBA1 gene, and is associated with a five-year mortality rate estimated at 30 to 40 percent. The condition predominantly affects men over the age of 50, and diagnosis is typically confirmed through genetic testing for UBA1 mutations in the bone marrow or blood. At present, according to GSK and independent clinical sources, there are no drugs specifically approved for VEXAS syndrome, and patients are often treated with high-dose steroids, immunosuppressants or off-label biologic therapies with varying success and significant toxicity.

By granting Orphan Drug Designation, the FDA and EMA are signaling that VEXAS syndrome is a serious, life-threatening condition affecting a small patient population, and that momelotinib has the potential to address an unmet medical need. Orphan status can confer benefits such as regulatory guidance, reduced fees and, upon approval, a period of market exclusivity for the specific indication, which can make it more attractive for companies to invest in clinical development for rare diseases. For GSK, the designations around VEXAS build on momelotinib’s existing mechanism as a JAK1/JAK2/ACVR1 inhibitor, with the company suggesting that the drug’s effects on inflammatory signaling and cytokine pathways could be relevant in a disease where hyperinflammation and hematologic involvement intersect. Importantly for patients and clinicians, Orphan Drug Designation does not mean that the drug is yet approved for VEXAS, but it does create a defined regulatory path for GSK to pursue full indication expansion if clinical data support it.

To explore this potential, GSK is sponsoring the phase II/III ATLAS trial, a global study designed to evaluate the efficacy and safety of momelotinib in adults with VEXAS syndrome. According to trial summaries, ATLAS will assess endpoints such as reduction in steroid use, improvement in inflammatory markers, symptom burden and hematologic parameters, although detailed endpoint hierarchies will be fully presented at the 2026 EHA Congress. The phase II component typically aims to determine dose and signal of activity, while the phase III portion is powered to support potential regulatory submissions if results are positive. For US patients, trial participation may provide earlier access to momelotinib in the VEXAS setting under clinical supervision, but enrollment criteria, study locations and inclusion rules are strictly defined and should be reviewed with a treating specialist or via official trial registries.

For people following rare disease innovation, the VEXAS designation and ATLAS trial underline how already-approved medicines can be repurposed into new indications when underlying biology points in that direction. Because momelotinib is already being used in real-world myelofibrosis populations, regulators and clinicians bring an existing understanding of its safety profile and pharmacology to the VEXAS investigation, potentially streamlining early-stage risk assessment. At the same time, the patient population in VEXAS is older and often burdened with multi-organ involvement and prior therapies, making careful monitoring of safety signals crucial as development progresses. For families and advocates in the US, Orphan Drug Designation can be an encouraging signal, but long-term access to a labeled therapy will depend on whether ATLAS or future studies demonstrate clear, clinically meaningful benefits that outweigh risks in a rigorous regulatory review.

For everyday US readers, the key takeaway is that Ojjaara remains, for now, a myelofibrosis drug in routine clinical practice, while VEXAS represents a separate rare disease area where momelotinib is under investigation rather than broadly available on prescription. Physicians interested in this research can consult the detailed protocol and emerging data as they are presented at scientific meetings and in peer-reviewed journals, and may discuss clinical trial referral with eligible patients. Patients who hear about momelotinib’s VEXAS designation in media reports should confirm with their specialists that the drug is not yet approved for this use and that participation in clinical trials is the structured pathway for receiving it in that indication. As clinical results accumulate, GSK has indicated that it will work with regulators in the US and globally to determine whether formal label expansion for VEXAS is warranted. For households affected by rare haematologic and inflammatory conditions, these steps can feel incremental, but they are how orphan-designated programs move from experimental status toward potential mainstream care.

For now, Ojjaara’s main practical relevance to US consumers lies in its approved use for myelofibrosis with anemia, a serious and debilitating condition but one for which targeted options exist, albeit at specialty pricing levels. Access in the US runs through oncologists and hematologists, with distribution via specialty pharmacies rather than typical retail drugstores, and coverage decisions shaped by insurance formularies and prior authorization processes. Questions around co-pays, coverage limits and patient support are typically addressed with a combination of insurer hotlines, provider office staff and programs run or funded by GSK, whose details can be found on the official Ojjaara product page or via the broader GSK site for US patients. As regulatory updates like the VEXAS Orphan Drug Designation accumulate, they may not change the day-to-day experience of current myelofibrosis patients immediately, but they can influence how clinicians and payers view the long-term strategic value of momelotinib as a versatile tool in complex blood and inflammatory diseases. Shares of GSK (GB0009252882, ticker GSK) traded on the NYSE at levels reported around mid-June 2026, reflecting a market that has taken note of both the Ojjaara franchise and the company’s broader rare disease and oncology pipeline.

This article was created with a.i. assistance and editorially reviewed. Product information is provided without warranty; prices and availability may change at any time. Not investment advice, not a buy or sell recommendation. Trading in securities carries risks up to the total loss of capital.